Bluebird bio announced Tuesday morning that it is laying off 25% of its workforce and cutting expenses by 20%. The move comes ...

The US House of Representatives on Monday afternoon unanimously passed a wide-ranging bill via voice vote that will ...

Metsera, the well-funded obesity biotech from Population Health Partners and ARCH Venture Partners, has unveiled its first ...

A UK-based synthetic biology startup has brought in $58 million from private investors to fund its work engineering cell ...

Biomedicines announced another pharma partnership Tuesday, agreeing to work on several protein therapies with the Swiss ...

Biogen and UCB said Tuesday morning that data from a Phase 3 study for the lupus program dapirolizumab pegol were strong ...

A software startup has sued Epic on antitrust grounds, arguing that the electronic health records giant has orchestrated a ...

A Johnson & Johnson subsidiary filed for bankruptcy in its third attempt to settle a vast majority of cases alleging its talc ...

As the federal government is threatening Johnson & Johnson with fines related to its unilateral alterations to the 340B drug ...

UCB’s Bimzelx scored three more FDA approvals on Monday, making it the first and only IL-17A and IL-17F inhibitor approved in ...

Plus, news about Longevity Biomedical, Sensorion, Teva and Bristol Myers Squibb: Context Therapeutics buys a T cell engager: The biotech will pay $15 million upfront and up to $118.5 million in ...

Black Diamond Therapeutics’ stock price $BDTX jumped more than 15% premarket Monday morning after the company reported its ...